Annexon

Annexon EBITDA per Employee

The EBITDA per Employee of Annexon (ANNX) as of Oct 11, 2026 is -2.25 M USD. In the previous year, EBITDA per Employee was -1.60 M USD — a change of 40.46% (lower).

EBITDA per Employee

-2.25 MUSD

YoY

40.46%

Last updated:

EBITDA per Employee of Annexon is 2025 -2.25 M USD. EBITDA per Employee of Annexon was 2024 -1.60 M USD. It decreases by 40.46% lower compared to the previous year.

The Annexon EBITDA per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Employee
Date
EBITDA per Employee
Jan 1, 2018
-199,447.92 USD
Jan 1, 2019
-338,729.17 USD
Jan 1, 2020
-661,135.42 USD
Jan 1, 2021
-1.36 M USD
Jan 1, 2022
-1.52 M USD
Jan 1, 2023
-1.50 M USD
Jan 1, 2024
-1.60 M USD
Jan 1, 2025
-2.25 M USD
The Annexon EBITDA per Employee history
YEAREBITDA per EmployeeYoY
-2.25 MUSD+40.46%
-1.60 MUSD+7.20%
-1.50 MUSD-1.29%
-1.52 MUSD+11.39%
-1.36 MUSD+105.95%
-661,135.42USD+95.18%
-338,729.17USD+69.83%
-199,447.92USD-6.50%
-213,302.08USD—
Access this data via the Eulerpool API

Annexon Stock analysis

What does Annexon do? Annexon Inc is a biopharmaceutical company based in South San Francisco, California. It was founded in 2011 by Doug Love, Ted Love, and Arnon Rosenthal, who had previously worked at major pharmaceutical companies such as Genentech and Novartis. The company's main goal is to develop new treatment options for neurodegenerative diseases, focusing on the development of drugs that target the autophagy process in cells to reduce damage to nerve cells and alleviate symptoms. Annexon Inc has two divisions, Annexon Biosciences and Annexon Clinical, with partnerships with renowned pharmaceutical companies to advance drug development. Its main product is ANX005, a therapeutic antibody protein that targets the role of the complement system in neurodegenerative diseases. Annexon Inc has received multiple awards for its work and innovations and has a dedicated team of scientists and executives committed to improving the lives of people with neurodegenerative diseases. Annexon is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Annexon stock

EBITDA per Employee of Annexon is -2.25 M USD in 2025.

EBITDA per Employee of Annexon changed from -1.60 M USD to -2.25 M USD, representing a 40.46% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Employee Annexon since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's Annexon historically and in real time.

Access this data via the Eulerpool API

Workforce — Annexon

All Key Metrics — Annexon